Brainstorm Cell Therapeutics BCLI
OTC BCLI
$0.77 -0.02 (-2.53%)
At close: Oct 21, 2026 · 4:00 PM EDT

Brainstorm Cell Therapeutics (BCLI) Debt Ratio (2010 - 2026)

Updated

Brainstorm Cell Therapeutics' Debt Ratio was 1.60 in Q2 2026, compared with 0.04 a year earlier and down 9.1% from the prior quarter.

Analysis

Brainstorm Cell Therapeutics (BCLI) Debt Ratio (2010 - 2026) Analysis & Trends

For FY2025, Debt Ratio at Brainstorm Cell Therapeutics came in at 0.95, up 477.8% from FY2024.

  • In earlier years, Debt Ratio was 0.16 in FY2024.
  • Quarterly Debt Ratio has moved between 0.04 (Q2 2025) and 1.76 (Q1 2026) over five years.
  • Per Business Quant data, BCLI's Debt Ratio in the three quarters before Q2 2026 was 1.76 (Q1 2026), 0.95 (Q4 2025) and 0.07 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 0.39
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 0.23
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 0.52
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 0.42
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 0.08
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 0.28
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 0.60
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 0.53
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 0.31
10 Brainstorm Cell Therapeutics 8.50 Mn 8.43 Mn - 1.60
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.60
Mar 31, 2026 1.76
Dec 31, 2025 0.95
Sep 30, 2025 0.07
Jun 30, 2025 0.04
Mar 31, 2025 0.34
Dec 31, 2024 0.16
Dec 31, 2010 0.13
API Access

Brainstorm Cell Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=BCLI&period=max&api_key=YOUR_API_KEY